Bupivacaine Effectiveness and Safety in SABER® Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

331

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Postoperative PainAbdominal Surgery
Interventions
DRUG

SABER-Bupivacaine

Injectable Extended Release Solution; SABER-Bupivacaine /Once

DRUG

Bupivacaine HCl

Injectable Solution; Bupivacaine HCl /Once

DRUG

SABER-Placebo

Injectable Solution; SABER-Placebo/Once

Trial Locations (26)

3128

DURECT Study Site, Box Hill

3135

DURECT Study Site, Ringwood East

5011

DURECT Study Site, Woodville South

8022

DURECT Study Site, Christchurch

10016

DURECT Study Site, New York

17033

DURECT Study Site, Hershey

27710

DURECT Study Site, Durham

30127

DURECT Study Site, Powder Springs

33606

DURECT Study Site, Tampa

35209

DURECT Study Site, Birmingham

35630

DURECT Study Site, Florence

35660

DURECT Study Site, Sheffield

36106

DURECT Study Site, Montgomery

36608

DURECT Study Site, Mobile

36617

DURECT Study Site, Mobile

43210

DURECT Study Site, Columbus

46206

DURECT Study Site, Indianapolis

48085

DURECT Study Site, Troy

55805

DURECT Study Site, Duluth

77024

DURECT Study Site, Houston

77375

DURECT Study Site, Temple

91007

DURECT Study Site, Arcadia

91105

DURECT Study Site, Pasadena

92335

DURECT Study Site, Fontana

92653

DURECT Study Site, Laguna Hills

02135

DURECT Study Site, Boston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Nycomed

INDUSTRY

collaborator

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Durect

INDUSTRY